GSTM1 and anemia: The 5-year LRFS, and DMFS rates of the different groups including pre-treatment anemia vs. pre-treatment no-anemia, mid-treatment anemia vs. mid-treatment no-anemia, Hb continuous decrease vs. noncontinuous decrease, and ΔHb < 2.2g/dl vs. ΔHb ≥ 2.2 g/dl are shown in Table 2.